Drug Amount Reporting: FDA Publicly Identifies over 7,700 Noncompliant Companies

Key Takeaways

• FDA lists over 7,700 firms missing 2024 drug amount reports
• 1,254 firms have active listings; 6,480 have inactive listings
• Non‑compliance hampers FDA’s ability to anticipate drug shortages
• Reporting required annually under CARES Act section 510(j)(3)
• Firms must audit listings twice yearly to avoid regulatory risk

Pulse Analysis

The CARES Act, enacted in 2020 to address pandemic‑related drug shortages, added a statutory reporting mandate to the FD&C Act. Under section 510(j)(3), every registered drug manufacturer, repacker or relabeler must submit an annual inventory of each listed product through the FDA’s NextGen Portal. The data feed the agency’s risk‑based inspection model, help map supply‑chain dependencies, and enable rapid response when a shortage looms. By requiring bi‑annual verification of listings, the rule aims to keep the national drug supply transparent and resilient.

The FDA’s March 31, 2026 release identified more than 7,700 registrants—1,254 with active and 6,480 with inactive listings—that failed to meet the 2024 deadline. This compliance gap erodes the agency’s visibility into production volumes, making it harder to flag emerging bottlenecks before they affect patients. While the posting stops short of naming enforcement actions, non‑submission signals regulatory risk and can trigger heightened scrutiny, including targeted inspections or civil penalties. Industry analysts warn that persistent gaps could undermine confidence in the U.S. drug supply chain and invite legislative pressure for stricter oversight.

To close the gap, companies should integrate drug‑amount reporting into existing quality‑management systems and assign clear ownership for bi‑annual data verification. Leveraging automated data‑capture tools can reduce manual errors and free resources for compliance monitoring. Moreover, proactive engagement with FDA’s NextGen Portal support teams helps resolve technical issues before filing deadlines. As the agency tightens supply‑chain transparency, firms that demonstrate consistent reporting will likely enjoy smoother inspection cycles and lower risk of penalties, positioning them as reliable partners in a market increasingly focused on resilience.